Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 28, 2022
YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAI’S SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS
-
December 23, 2022
ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER
-
December 23, 2022
EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
-
December 22, 2022
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
-
December 20, 2022
EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA® (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS
-
December 16, 2022
EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM
-
December 15, 2022
EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES
-
December 1, 2022
EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM
-
November 30, 2022
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 30, 2022
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER’S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE
-
November 29, 2022
(REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER
-
November 29, 2022
EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES
-
November 24, 2022
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
-
November 22, 2022
To Develop Japan’s First Blood Biomarker-Based Diagnostic Workflow for Dementia
Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
-
November 21, 2022
EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
-
November 16, 2022
METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS
-
November 7, 2022
EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON® IN ASIA TO DKSH
-
November 4, 2022
EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMER’S DISEASE, IN THAILAND
-
November 2, 2022
EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON®
-
October 31, 2022
EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT® FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION
-
October 4, 2022
EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
TO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS
-
September 28, 2022
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE
-
September 26, 2022
Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange
(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act)
-
September 26, 2022
METOJECT® SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS
-
September 21, 2022
RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMER’S DAY, SEPTEMBER 21
“LEARNING HELPS US TO BE KIND” LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP
-
September 12, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
-
September 12, 2022
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN®) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies
-
September 6, 2022
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combination’s Potential Across Difficult-to-Treat Cancers
Post-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulin’s Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisai’s Commitment to Advancing Understanding of Our Medicines
-
August 30, 2022
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION
-
August 24, 2022
EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS
-
August 12, 2022
HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH
-
August 9, 2022
EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE
-
August 4, 2022
EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
August 3, 2022
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
-
July 26, 2022
EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 26, 2022
EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER’S DISEASE RESEARCH AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022
-
July 25, 2022
AΒ-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE
-
July 15, 2022
REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS <effective as of July 15, 2022>
-
July 6, 2022
THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI’S BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
June 29, 2022
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 28, 2022
E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF “IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING”
-
June 24, 2022
EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP “KIGALI DECLARATION” FOR ELIMINATING NEGLECTED TROPICAL DISEASES
CEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES
-
June 22, 2022
EISAI’S “NOUKNOW®”, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
-
June 22, 2022
EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL
Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling
-
June 8, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023
-
June 6, 2022
EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING
Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)
Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090)
-
June 3, 2022
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
-
May 30, 2022
Announcement of a Summary Share Exchange (kan’i kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary
-
May 27, 2022
EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022
Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai’s Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients
Presentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma
-
May 27, 2022
MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS
-
May 20, 2022
“MOVICOL® HD” Launched
A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan
-
May 13, 2022
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2022
Notification Regarding Partial Amendment to the Articles of Incorporation
-
May 13, 2022
CHANGES OF CORPORATE OFFICERS
-
May 10, 2022
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
-
May 10, 2022
EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
-
May 3, 2022
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022
-
April 27, 2022
Discontinuance (abolition) of the Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders
-
April 27, 2022
LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY
-
April 8, 2022
EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
April 1, 2022
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
-
March 28, 2022
Announcement about an approval for additional indication of Jyseleca®, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
Approval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis
-
March 22, 2022
Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s Disease
The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)
-
March 22, 2022
LATEST FINDINGS ON LECANEMAB – CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS – PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
-
March 15, 2022
ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER‘S DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN
-
March 15, 2022
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
-
March 11, 2022
EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD™ 2022 ANNUAL MEETING
-
March 9, 2022
EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500)
-
March 7, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
-
March 4, 2022
EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB
-
February 25, 2022
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Results From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer
-
February 10, 2022
EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES’ PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
February 1, 2022
EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR® 2021
-
January 31, 2022
LENVIMA®（LENVATINIB）IN COMBINATION WITH KEYTRUDA®（PEMBROLIZUMAB）APPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
-
January 28, 2022
EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES
10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP “LONDON DECLARATION”
-
January 28, 2022
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
-
January 20, 2022
Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
-
January 19, 2022
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 19, 2022
FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU
EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY
-
January 17, 2022
EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM
-
January 13, 2022
Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
January 13, 2022
EISAI TO LAUNCH DIGITAL TOOL “CogMate™” IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH)
-
January 6, 2022
EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR
